Dr. William W. Li, M.D.
Dr. William Li is a seasoned executive, leading innovation in cancer therapeutics, diagnostics, and imaging for over two decades. He is CEO, President and Co-Founder of the Angiogenesis Foundation and has served as executive strategic consultant in oncology drug development with Bayer, Genentech, Sanofi-Aventis, Novartis, Pfizer, among others, and advised leaders at major investment banks. As an eminent oncology innovator, Dr. Li has collaborated with major medical academic centers, biopharmaceutical companies and government agencies, including the NIH, NCI and FDA. Dr. Li has extensive expertise in tumor angiogenesis, in vivo angiogenesis models, angiogenesis therapeutic development and clinical trials. He is a published author in leading research journals, peer reviewed publications and has been a speaker at TED. A graduate of Harvard College and the University of Pittsburgh School of Medicine, Dr. Li completed his residency training at the Massachusetts General Hospital. Dr. Li has held appointments on the clinical faculties of Harvard Medical School, Tufts University, and at Dartmouth Medical School. He is currently a member of the board of directors at Leap Therapeutics, Inc (LPTX, Nasdaq) and Ceapro Inc (CZO, TSX.V).